Susan Cohn to N-Myc Proto-Oncogene Protein
This is a "connection" page, showing publications Susan Cohn has written about N-Myc Proto-Oncogene Protein.
Connection Strength
1.705
-
Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma. J Natl Cancer Inst. 2017 10 01; 109(10).
Score: 0.538
-
MYCN and HIF-1 directly regulate TET1 expression to control 5-hmC gains and enhance neuroblastoma cell migration in hypoxia. Epigenetics. 2022 12; 17(13):2056-2074.
Score: 0.188
-
Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group. Am J Surg Pathol. 2021 08 01; 45(8):1075-1081.
Score: 0.175
-
A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2021 03; 68(3):e28794.
Score: 0.167
-
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. J Clin Oncol. 2020 11 01; 38(31):3685-3697.
Score: 0.165
-
Locoregional MYCN-amplified neuroblastoma. Pediatr Blood Cancer. 2012 Oct; 59(4):736-8.
Score: 0.090
-
Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification. J Clin Oncol. 2023 06 10; 41(17):3149-3159.
Score: 0.049
-
Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 01 10; 37(2):115-124.
Score: 0.036
-
Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study. Br J Cancer. 2015 Jun 30; 113(1):57-63.
Score: 0.029
-
Age-dependent prognostic effect by Mitosis-Karyorrhexis Index in neuroblastoma: a report from the Children's Oncology Group. Pediatr Dev Pathol. 2014 Nov-Dec; 17(6):441-9.
Score: 0.027
-
Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol. 2014 Oct 01; 32(28):3169-76.
Score: 0.027
-
Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014 Nov; 61(11):1932-9.
Score: 0.027
-
Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014 Apr; 61(4):627-35.
Score: 0.025
-
Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group. Cancer. 2013 Oct 15; 119(20):3718-26.
Score: 0.025
-
Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. Br J Cancer. 2012 Oct 09; 107(8):1418-22.
Score: 0.024
-
Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee. Pediatr Blood Cancer. 2013 Mar; 60(3):363-70.
Score: 0.023
-
Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: a report from the INRG project. Eur J Cancer. 2012 May; 48(8):1185-91.
Score: 0.022
-
Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. J Clin Oncol. 2011 Nov 20; 29(33):4358-64.
Score: 0.022
-
ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. J Natl Cancer Inst. 2011 Aug 17; 103(16):1236-51.
Score: 0.022
-
Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol. 2011 Aug 20; 29(24):3286-92.
Score: 0.022